2022 World Conference on Lung Cancer (ePosters)-EP08.02-135. Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)

EP08.02-135. Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)

Back to course

Pdf Summary

A study investigated the effects of anti-EGF antibodies on the activity of MET and KRAS inhibitors in non-small cell lung cancer (NSCLC) models. The researchers found that anti-EGF antibodies enhanced the efficacy of MET and KRAS inhibitors in these models. The study utilized various inhibitors and analyzed their effects on cell viability and activation of proteins in the EGF/EGFR pathway. The results showed that treatment with anti-EGF antibodies along with MET and KRAS inhibitors improved cell viability compared to treatment with the inhibitors alone. The study also examined the effects of different concentrations of the inhibitors and found that higher concentrations were associated with decreased cell viability and decreased activation of proteins in the EGF/EGFR pathway. <br /><br />Overall, the study suggests that combining anti-EGF antibodies with MET and KRAS inhibitors could be a promising approach for NSCLC treatment. The study also examined the effects of anti-EGF VacAbs, specifically IN01 antibodies, on the activity of capmatinib, tepotinib, and sotorasib in NSCLC cell lines with MET amplification and KRAS mutation. The researchers found that IN01 antibodies enhanced the effects of these inhibitors, leading to decreased cell viability and colony formation. The combination therapy also affected the phosphorylation of EGFR and downstream signaling molecules. This suggests that targeting EGF with VacAbs could enhance the efficacy of MET and KRAS inhibitors in NSCLC patients with specific genetic alterations. A clinical trial combining afatinib and anti-EGF VacAbs has also shown promising results in terms of progression-free survival in EGFR-mutant NSCLC, supporting the potential of VacAbs as an alternative to anti-EGFR monoclonal antibodies. Overall, the study provides evidence for the potential of combining anti-EGF antibodies or VacAbs with MET and KRAS inhibitors in NSCLC treatment, specifically in patients with specific genetic alterations.

Asset Subtitle

Silvia Garcia-Roman

Meta Tag

Speaker Silvia Garcia-Roman

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

anti-EGF antibodies

MET inhibitors

KRAS inhibitors

non-small cell lung cancer

cell viability

EGF/EGFR pathway

EGF VacAbs

MET amplification

KRAS mutation

colony formation